Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts.
about
Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patientsRole of the gut microbiota in defining human healthCharacteristics of the Clostridium difficile cell envelope and its importance in therapeuticsAntibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of ResistancesDisruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic ResistanceCrossing the scale from within-host infection dynamics to between-host transmission fitness: a discussion of current assumptions and knowledgeMurine models to study Clostridium difficile infection and transmissionThe intestinal microbiota and susceptibility to infection in immunocompromised patientsControl of pathogens and pathobionts by the gut microbiotaHost recognition of Clostridium difficile and the innate immune response.Emerging insights on intestinal dysbiosis during bacterial infectionsSalmonella transiently reside in luminal neutrophils in the inflamed gutClostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteriaMetabolism of bile salts in mice influences spore germination in Clostridium difficileSalmonella-induced mucosal lectin RegIIIβ kills competing gut microbiotaIdentification of a Novel Lipoprotein Regulator of Clostridium difficile Spore GerminationClostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventionsMulti-functional nano silver: A novel disruptive and theranostic agent for pathogenic organisms in real-timeThe microbiota and immune response during Clostridium difficile infection.Inference of Network Dynamics and Metabolic Interactions in the Gut MicrobiomeStereomicroscopic 3D-pattern profiling of murine and human intestinal inflammation reveals unique structural phenotypesFecal microbiota transplantation: effectiveness, complexities, and lingering concerns.Functional genomics reveals that Clostridium difficile Spo0A coordinates sporulation, virulence and metabolismDominant and diet-responsive groups of bacteria within the human colonic microbiota.The Clostridium difficile cell wall protein CwpV is antigenically variable between strains, but exhibits conserved aggregation-promoting functionIdentification and characterization of glycoproteins on the spore surface of Clostridium difficileA role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins.Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis.The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile.Clostridium difficile and the microbiotaMicrobiota-mediated colonization resistance against intestinal pathogens.Oral and airway microbiota in HIV-infected pneumonia patients.Shedding light on the microbial community of the macropod foregut using 454-amplicon pyrosequencingVancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans.Clostridium difficile spore-macrophage interactions: spore survival.Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota.Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in miceIdentification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficileCharacterisation of Clostridium difficile biofilm formation, a role for Spo0A.Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC
P2860
Q21562196-82F8470B-7D85-4B0C-A737-CC75535460ABQ24599062-D06BE62F-612D-4292-861B-807B09486293Q26745652-7E97ECCA-4A5C-4F75-B4C9-2CFB5F2857FFQ26770392-A59B61B3-CB2C-4897-8713-02FC0D3C2B62Q26771995-87C1128A-A5E8-4D54-85C7-F93A97C932CDQ26824525-F8BCFC83-3C11-494A-8797-05757A08AE93Q26859965-DD06CA71-0D49-4B84-AC08-55EF69D645F8Q26862848-C9766170-835E-46C8-B112-EDBF68A6DC93Q27013060-724E02C9-36A1-41E4-989D-447F89B9673DQ27026464-B4A3052F-8A65-4057-8835-6C23274ED940Q27027423-0CD68706-73C4-4B77-8AAD-C8BC8D34219BQ27304991-55A8CB2E-AE12-4858-9825-554BAD4D2C31Q27316166-FCF54504-AA5C-4F0E-BA2F-D7BA5CFC56FCQ28472543-9BD9EB12-FEA0-49C2-8BA9-36D5316BE11CQ28504981-7E88948A-757D-48D4-84A8-E0A8E8F81443Q28550467-EDB72C09-E669-4841-BC89-C413532E0034Q28743438-BB2E8F7C-145C-4D50-B3D9-DDD325407780Q28829073-FA208FFB-3BA3-4291-BCC7-2A5238C97302Q30276756-3242DB99-7681-45F6-B6F0-BA9ED6BA1F98Q30384334-AF3114E4-93E6-4FFE-A1F7-EBC6073656DAQ30658529-6095E562-4773-45A5-9162-63424C606FF5Q31147407-7C78427E-A599-4CBA-ACC0-5DFFD18A1753Q33641301-8BB91C36-8CEE-4307-9153-57444CB8F1D0Q33649520-B07F9070-468B-44C2-8FE7-FDAC9160C692Q33886149-4F7849E8-002B-413E-A666-2F8E29FE2EB2Q33899557-F793430D-CBF2-4593-ADAE-17DCC84E6EAFQ33954369-C324FD2D-A229-4E95-8BA3-D7212216E7A7Q34050235-1B2CB573-8662-496D-9904-5DE763DDA032Q34055302-61561883-A647-4DA5-BFFE-7DA92F01A81EQ34311594-87C56797-B17B-4B10-8141-08CD4B9E3D03Q34324937-A266A77A-740D-43AD-87F5-3274DA8F0773Q34325140-9466CAA0-A5D8-4D5E-BD5A-8F2504F1F5A6Q34341713-E1EC75D5-EF03-4796-A93E-29A6564519A9Q34360221-601A32C0-D0EE-41C0-8A61-FFAE5E363BE6Q34405411-FD67CB67-B0E8-4E5C-932B-74DB1DC9B7BCQ34444065-542ECB0E-BA96-486E-8D93-4E068A3C267BQ34468946-4748E1F2-29C0-4A59-8CA1-E04B1D29E353Q34484594-91FE7B55-4AE4-468E-8AEA-328944CF5379Q34510386-001FA80F-A01F-4DFA-95D5-57673DB22FF3Q34512085-B3A2F8EB-7EFF-460F-B3F3-F3B023A03383
P2860
Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antibiotic treatment of clostr ...... se in immunocompromised hosts.
@en
Antibiotic treatment of clostr ...... se in immunocompromised hosts.
@nl
type
label
Antibiotic treatment of clostr ...... se in immunocompromised hosts.
@en
Antibiotic treatment of clostr ...... se in immunocompromised hosts.
@nl
prefLabel
Antibiotic treatment of clostr ...... se in immunocompromised hosts.
@en
Antibiotic treatment of clostr ...... se in immunocompromised hosts.
@nl
P2093
P2860
P50
P356
P1476
Antibiotic treatment of clostr ...... se in immunocompromised hosts.
@en
P2093
Claire Raisen
David Goulding
Gordon Dougan
Lynda Mottram
Neil F Fairweather
Nicholas Croucher
Paul Scott
Piero Mastroeni
Simon Clare
Trevor D Lawley
P2860
P304
P356
10.1128/IAI.00558-09
P407
P577
2009-06-29T00:00:00Z